
Bafna Pharmaceuticals Ltd is Rated Hold
2026-11-21 10:10:04Bafna Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 11 November 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 21 November 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More
Bafna Pharmaceuticals Ltd Reports Strong Quarterly Performance Amid Financial Trend Reversal
2026-11-17 08:00:11Bafna Pharmaceuticals Ltd has delivered its highest quarterly performance to date in September 2026, marking a significant turnaround from previous negative financial trends. Despite a recent downgrade in market sentiment, the company’s latest results reveal robust revenue growth, margin expansion, and improved profitability metrics, signalling a potential inflection point for this micro-cap player in the Pharmaceuticals & Biotechnology sector.
Read More
Bafna Pharmaceuticals Ltd Hits New 52-Week High of Rs 504 on Back of Strong Technical Signals
2026-11-13 10:44:21From a 52-week low of Rs 95 to a fresh peak of Rs 504, Bafna Pharmaceuticals Ltd has surged an impressive 172.21% over the past year, significantly outperforming the Sensex which declined by 3.21% in the same period. This remarkable rally culminated in the stock hitting an all-time high today, driven predominantly by a broad alignment of technical indicators signalling sustained momentum.
Read More
Broad-Based Technical Strength Lifts Bafna Pharmaceuticals Ltd to 52-Week High of Rs 494.15
2026-11-12 10:35:37From a 52-week low of Rs 95 to a fresh peak of Rs 494.15, Bafna Pharmaceuticals Ltd has surged an impressive 161.6% over the past year, outpacing the Sensex which declined 2.7% in the same period. This remarkable rally culminated on 12 Nov 2026, as the stock touched its new all-time high, fuelled by a confluence of strong technical signals and sustained price momentum.
Read More
Bafna Pharmaceuticals Ltd is Rated Sell
2026-11-10 10:10:30Bafna Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 May 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 10 November 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.
Read More
Bafna Pharmaceuticals Ltd is Rated Sell
2026-10-24 10:10:27Bafna Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 24 October 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More
Bafna Pharmaceuticals Ltd Hits New 52-Week High of Rs 487.45 on Back of Strong Technical Signals
2026-10-21 10:40:47Surging past its previous peaks, Bafna Pharmaceuticals Ltd touched an all-time high of Rs 487.45 on 21 Oct 2026, marking a remarkable rally from its 52-week low of Rs 95. This 413.1% increase over the past year stands in stark contrast to the Sensex’s 12.08% decline, underscoring the stock’s exceptional momentum amid a challenging market backdrop.
Read More
Bafna Pharmaceuticals Ltd Hits New 52-Week High of Rs 469.8 on Back of Strong Technical Signals
2026-10-19 10:36:49From a 52-week low of Rs 95 to a fresh peak of Rs 469.8, Bafna Pharmaceuticals Ltd has surged an impressive 203.78% over the past year, outpacing the Sensex which declined by 11.29% in the same period. This remarkable rally culminated in the stock hitting a new all-time high on 19 Oct 2026, fuelled by a confluence of bullish technical indicators and sustained price momentum.
Read More
Broad-Based Technical Strength Lifts Bafna Pharmaceuticals Ltd to 52-Week High of Rs 459.95
2026-10-15 10:37:38With a remarkable 48.88% gain over the past 21 trading sessions, Bafna Pharmaceuticals Ltd surged to a fresh 52-week and all-time high of Rs 459.95 on 15 Oct 2026, showcasing a powerful momentum that has captivated market attention.
Read MoreAnnouncement under Regulation 30 (LODR)-Newspaper Publication
16-Nov-2026 | Source : BSEWe herewith enclose the Newspaper Publication for the Unaudited Financial Results of the Company for the Quarter & Half Year ended September 30 2026 as published in Business Standard and Makkal Kural on November 13 2026.
Unaudited Financial Results For The Quarter And Half Year Ended September 30 2026
11-Nov-2026 | Source : BSEWe herewith enclose the Unaudited Financial Results for the Quarter and Half Year ended September 30 2026 as approved by the Board of Directors in its Meeting held on November 11 2026.
Board Meeting Outcome for The Board Meeting Held On 11/11/2026
11-Nov-2026 | Source : BSEWe hereby inform you that the Board of Directors in its Meeting held on November 11 2026 inter-alia considered and approved the Unaudited Financial Results of the Company along with the Limited Review Report issued by the Statutory Auditors for the Quarter and Half Year ended September 30 2026.
Corporate Actions
No Upcoming Board Meetings
Bafna Pharmaceuticals Ltd has declared 6% dividend, ex-date: 19 Sep 13
No Splits history available
No Bonus history available
No Rights history available